We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

GC Labs Highlight Its “Smart Lab” Concept at MEDLAB Middle East 2022

By LabMedica International staff writers
Posted on 24 Jan 2022
Print article
Image: GC Labs Highlight Its `Smart Lab` Concept at MEDLAB Middle East 2022  (Photo courtesy of GC Labs)
Image: GC Labs Highlight Its `Smart Lab` Concept at MEDLAB Middle East 2022 (Photo courtesy of GC Labs)

GC Labs (Yongin, South Korea) participated in the 2022 edition of MEDLAB Middle East held at the Dubai World Trade Centre (DWTC) from January 24 to 27 where it offered a ‘smart experience’ for visitors to learn more about the diagnostic services offered by the company.

At the event, GC Labs highlighted its “smart lab” concept that provides an automated test system to improve speed and efficiency of tests, allowing the company to report results in just a day or two. The increase in demand for genetics and infectious disease tests in the region has prompted GC Labs to plan further expansion in the Middle East. Currently offering their services in Saudi Arabia and the UAE, the company is in talks with regional partners to expand their services to more countries in the Middle East. More than 800 employees at GC Labs offer over 5,000 tests and test combinations, ranging from routine tests to highly esoteric molecular and genetic assays.

GC Labs hosted its seminar on ‘Public-Private Partnership in Global Health: bringing the best of both worlds to improve testing’ on January 25 at the Bubble Lounge in Medlab. The seminar had an impressive line-up of speakers with globally renowned specialists including Lelio Marmora, former CEO in Unitaid; Michel Kazatchkine, former executive director the Global Fund to Fight AIDS, TB and Malaria; Dr Eskild Petersen, MD, Editor-in-chief of IJID Regions, an official journal of the International Society for Infectious Diseases (ISID); Dr Amina Al-Jardani, Director of Central Public Health Laboratories (CPHL), Directorate General for Disease Surveillance and Control, Ministry of Health, Oman; and Lee. The seminar was an interactive session with an opportunity for attendees to ask questions.

“The Middle East is an important market for us, and participating in MEDLAB will help us to share our best practices in clinical diagnostics with the regional health community. Over the past two decades, the world has achieved important success in the fight against pandemics like COVID-19 and in mobilizing global response against HIV-Aids, TB, Malaria and other infectious diseases,” said Eun-Hee Lee, President at GC Labs. “Medical laboratories play a key role in this fight by providing high quality diagnostic testing and by working in partnership with the health authorities. To highlight the importance of private and public partnership in the fight against infectious diseases and pandemics, we are organizing a seminar during MEDLAB to bring together international experts to share their own experiences and expertise, focus on lessons learned, and discuss how to best manage public and private partnerships to successfully fight against pandemics and infectious diseases in the future.”

Related Links:
GC Labs 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more


view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.